Mylan (NSDQ:MYL) revealed in its annual report yesterday that EpiPen sales in the U.S. were down $655.4 million last year compared to 2016. The company, which faces continued backlash over the price of its emergency allergy treatment, cited the launch of a generic version of its device, higher governmental rebates and increased competition as reasons for […]
Featured
Sorrento Therapeutics wins FDA nod for post-shingles pain patch
Shares in Sorrento Therapeutics (NSDQ:SRNE) soared today after the company announced that the FDA approved its ZTlido lidocaine pain patch designed to treat patients with post-shingles neuralgia. The company resubmitted its application for ZTlido to the FDA last year after it was rejected by the U.S. regulatory agency in 2016. “ZTlido was designed to solve a […]
Study: Hill-Rom’s Metaneb System lowers risk of post-operative pulmonary complications
Researchers at the 47th Society of Critical Care Medicine reported this week that Hill-Rom‘s (NYSE:HRC) Metaneb System may help reduce the incidence of post-operative pulmonary complications in high-risk patients. A 419-patient study found that patients using the Metaneb System combined with standard respiratory therapy spent 1.6 fewer days in the hospital on average compared to […]
Intersect ENT posts Street-beating Q4, full-year sales, earnings
Shares in Intersect ENT (NSDQ:XENT) rose today after the medical device maker topped expectations on Wall Street with its fourth quarter and full-year financial results. The Menlo Park, Calif.-based company posted a net loss of -$3.2 million, or-11¢ per share, on sales of $29.5 million for the three months ended Dec. 31, for sales growth of […]
Dexcom beats The Street with Q4 sales, earnings
Dexcom (NSDQ:DXCM) beat expectations on Wall Street with its fourth quarter and full year financial results, growing its quarterly revenue 29% compared to the same period last year. The San Diego, Calif.-based company posted a net loss of -$9.4 million, or -11¢ per share, on sales of $221 million for the 3 months ended Dec. 31. […]
Facing legal woes, PixarBio takes aim at InVivo
PixarBio (OTC:PXRB) faces its own legal problems: a possible lawsuit by the SEC, legal action by a disgruntled employee who is demanding unpaid wages and former landlords looking for $1.8 million in unpaid rent. But the 7-person biotech is also looking to launch some litigation of its own, according to a recent document it filed with […]
EMA committee backs Amgen’s on-body injector for Neulasta
Amgen (NSDQ:AMGN) said today that a committee for the European Medicines Agency has recommended that the regulatory body approve a label variation for its Neulasta product to include the Onpro on-body injector delivery device. Neulasta’s Onpro kit includes a pre-filled syringe paired with a single-use on-body injector. The lightweight device is given to the patient on the […]
Abbott, Surmodics ink $25m deal for drug-coated balloon tech
Abbott (NYSE:ABT) is slated to pay $25 million upfront for the global commercialization rights to Surmodics‘ (NSDQ:SRDX) SurVeil drug-coated balloon, the companies announced today. The company’s drug-device combo, which is in pivotal trials in the U.S., is designed to treat peripheral artery disease in the superficial femoral artery. According to the deal, Abbott could also negotiate […]
Medtronic thinks these clinics could be the future of diabetes care – here’s why
Updated to include comments from David Kaplan. Managing a chronic illness can feel like a full-time job. Between juggling multiple appointments with an array of specialists and following a meticulous care plan, patients dealing with conditions like diabetes have a lot on their plate. Medtech titan Medtronic (NYSE:MDT) wants to help change that. The company’s CEO […]
Anthem exec chairman joins Proteus board | Personnel Moves – Feb. 26, 2018
Proteus Digital Health announced earlier this month that Anthem‘s (NYSE:ANTM) executive chairman, Joseph Swedish, joined the company’s board of directors. Swedish served as Anthem’s president & chief executive from 2013 until he was appointed executive chairman in 2018. “Proteus has created a compelling solution to a problem that has plagued the pharmaceutical industry for decades: […]